TNF-α -857 and -1031 Polymorphisms Predict Good Therapeutic Response to TNF-α Blockers in Chinese Han Patients with Ankylosing Spondylitis.

Qiang Tong,Dong-Bao Zhao,Punam Bajracharya,Xia Xu,Rui-Na Kong,Ju Zhang,Sheng-Ming Dai,Qing Cai
DOI: https://doi.org/10.2217/pgs.12.133
2012-01-01
Pharmacogenomics
Abstract:Aim: To evaluate whether polymorphisms at -857, -1031, -308 and -238 positions of the TNF-alpha gene influence response to TNF-alpha-blocker therapy in Chinese Han patients with ankylosing spondylitis. Patients & methods: A total of 106 patients with ankylosing spondylitis were recruited and genotyped for -857, -1031, -308 and -238 TNF-alpha gene polymorphisms. In total, 32 received infliximab and 74 received a recombinant human TNF-alpha receptor II-IgG Fc fusion protein (rhTNFR-Fc). At the end of 12 weeks, patients were assessed using the Assessment of SpondyloArthritis International Society (ASAS) 20, 40, 50 and 70 criteria. Results: Polymorphisms at -308 and -238 did not affect therapeutic response. The -857 C/C genotype (p = 0.0021) responded better to therapy. The -1031 T/T genotype (p = 0.0004) showed better outcome. Conclusion: In Chinese Han ankylosing spondylitis patients, polymorphisms at the -308 and -238 positions of the TNF-alpha gene are unable to predict TNF-alpha-blocker response; however, -857 C/C and -1031 T/T genotypes have the ability to predict good response.
What problem does this paper attempt to address?